8月11日 - ** 药物研发公司 C4 Therapeutics CCCC.O 股价上涨 2.5%，报 3.68 美元
** 该公司第二季度营收 为660万美元，超出分析师平均预期的400万美元
** C4表示，营收增长主要源于与瑞士制药商罗氏 ROPC.S 签署的新合作协议所确认的收入
** 双方正合作开发高度靶向的抗癌药物，通过结合两种不同技术，研制一种名为“降解剂-抗体偶联物”（Degrader-Antibody Conjugate）的新型药物
** 据伦敦证券交易所集团（LSEG）数据显示，C4报告第二季度每股亏损18美分 ，而分析师平均预期为 每股亏损23美分
** 计入当日涨幅在内，该股今年以来累计上涨89.5%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.